Effects of neonatal treatment with 5,7-dihydroxytryptamine or 6-hydroxydopamine on the ontogenetic development of the audiogenic immobility reaction in the rat
✍ Scribed by Ernest Hård; Sven Ahlenius; Jörgen Engel
- Publisher
- Springer
- Year
- 1983
- Tongue
- English
- Weight
- 722 KB
- Volume
- 80
- Category
- Article
- ISSN
- 0033-3158
No coin nor oath required. For personal study only.
✦ Synopsis
The ontogenetic development of the audiogenic immobility reaction (freezing) was studied in rats given intracisternal injections of the neurotoxins 5,7-dihydroxytryptamine (5,7-DHT), 25 gg, or 6-hydroxydopamine (6-OHDA), 100 gg, neonatally (Day 1). The duration of the freezing response was strongly reduced in the 5,7-DHTtreated rats between 20" 30 days of age, when normal animals show very prolonged responses. During the same period increased motor activity was observed in the 6-OHDA-treated rats while only a slight reduction of the freezing response was noted. Biochemical analyses performed on brains from animals 35 days of age showed a selective reduction (about 50 %) of whole brain levels of serotonin in the 5,7-DHT-treated rats, while the noradrenaline levels were selectively reduced by about 60 % in the 6-OHDA rats. A longitudinal investigation on the effects of neonatal treatment with 5,7-DHT showed a persistent selective reduction of the whole brain level of serotonin up to at least 90 days of age. Since 5,7-DHT mainly affects the serotonergic pathways, the results suggest that the disturbances noted in the ontogeny of the freezing response may be due to interference with the developing serotonergic system.
📜 SIMILAR VOLUMES
The intrastriatal injection of 6-hydroxydopamine (6-OHDA) in newborn rats produces a marked striatal dopamine (DA) depletion, accompanied by a serotonin (5-HT) hyperinnervation and an up-regulation of 5-HT receptors. The aim of the present study was to investigate whether the increase in 5-HT 2 rece
## Abstract This study was designed to test whether chronic treatment with the metabotropic glutamate receptor 5 (mGlu5R) antagonist MPEP showed antiparkinsonian effects in rats unilaterally lesioned with 6‐hydroxydopamine (6‐OHDA) (a “classic” model of Parkinson's disease, PD), and to evaluate whe